The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

effrx.com

Stage

Secondary Market | Alive

Total Raised

$10.25M

About EffRx Pharmaceuticals

EffRx Pharmaceuticals exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential. Once developed, the company partners these products with established pharmaceutical companies. EffRx's goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying our technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action.

EffRx Pharmaceuticals Headquarter Location

Wolleraustrasse 41B

Freienbach, CH-8807,

Switzerland

+41 44 503 78 60

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EffRx Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EffRx Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

EffRx Pharmaceuticals Patents

EffRx Pharmaceuticals has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/5/2011

3/14/2017

Excipients, Conditions of the mucous membranes, Oral mucosal pathology, Salivary gland pathology, Dosage forms

Grant

Application Date

12/5/2011

Grant Date

3/14/2017

Title

Related Topics

Excipients, Conditions of the mucous membranes, Oral mucosal pathology, Salivary gland pathology, Dosage forms

Status

Grant

Latest EffRx Pharmaceuticals News

WODA combining forces to reach patients with rare diseases across globe

May 13, 2022

13 May 2022 | News Image credit: shutterstock EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC, and Vector Pharma, announced the newly formed World Orphan Drug Alliance (WODA). WODA aims to provide comprehensive support to pharmaceutical and biotech companies with rare diseases, oncology and highly specialized therapeutics portfolio, starting from named patient programs through to full commercialization. By bringing together experts for rare diseases, WODA has capabilities to provide all the services necessary for orphan medicines to reach patients in need, replacing local branches of global distributors or multinational companies. In total, WODA covers 68 countries in the following regions: Turkey, Middle East and North Africa, Russia and CIS region, Central and Eastern Europe, Latin America and Switzerland. About Founding Partners: EffRx Pharmaceuticals is a Switzerland based company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. Medis based in Slovenia is the commercialization partner of choice for innovative pharmaceutical and biotech companies seeking strong business growth in Central and Eastern Europe. Orpharm is a Moscow based full-service distributor covering Russia and the Commonwealth of Independent States (CIS). OrphanDC based in Sao Paolo, Brazil acts as a partner for biotech companies in Latin America. They focus on supporting their clients from the clinical development stage throughout the product lifecycle. Vector Pharma is a Dubai based full-service distributor covering Middle East, North Africa and Turkey. Sign up for the editor pick and get articles like this delivered right to your inbox. Name *

EffRx Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EffRx Pharmaceuticals Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.